[go: up one dir, main page]

PL2010209T3 - Immunogeniczne peptydy WT-1 i sposoby ich użycia - Google Patents

Immunogeniczne peptydy WT-1 i sposoby ich użycia

Info

Publication number
PL2010209T3
PL2010209T3 PL07755205T PL07755205T PL2010209T3 PL 2010209 T3 PL2010209 T3 PL 2010209T3 PL 07755205 T PL07755205 T PL 07755205T PL 07755205 T PL07755205 T PL 07755205T PL 2010209 T3 PL2010209 T3 PL 2010209T3
Authority
PL
Poland
Prior art keywords
immunogenic
peptides
methods
Prior art date
Application number
PL07755205T
Other languages
English (en)
Inventor
A. SCHEINBERG David
Rena May
Original Assignee
Sloan Kettering Inst For Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Inst For Cancer Res filed Critical Sloan Kettering Inst For Cancer Res
Publication of PL2010209T3 publication Critical patent/PL2010209T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/868—Vaccine for a specifically defined cancer kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL07755205T 2006-04-10 2007-04-10 Immunogeniczne peptydy WT-1 i sposoby ich użycia PL2010209T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79052606P 2006-04-10 2006-04-10
US85200906P 2006-10-17 2006-10-17

Publications (1)

Publication Number Publication Date
PL2010209T3 true PL2010209T3 (pl) 2017-04-28

Family

ID=38610136

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07755205T PL2010209T3 (pl) 2006-04-10 2007-04-10 Immunogeniczne peptydy WT-1 i sposoby ich użycia

Country Status (6)

Country Link
US (4) US9265816B2 (pl)
EP (3) EP3117836A1 (pl)
CA (1) CA2645766A1 (pl)
ES (1) ES2591029T3 (pl)
PL (1) PL2010209T3 (pl)
WO (1) WO2007120673A2 (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2071028T3 (pl) 2003-11-05 2012-06-29 Int Inst Cancer Immunology Inc Pochodzący z WT1 peptyd antygenowy wiążący się z HLA-DR
EP2565201B1 (en) 2005-10-17 2014-11-26 Sloan-Kettering Institute For Cancer Research WT1 HLA class II-binding peptides and compositions and methods comprising same
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
EP3117836A1 (en) 2006-04-10 2017-01-18 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and uses thereof
ES2559062T3 (es) 2007-02-27 2016-02-10 International Institute Of Cancer Immunology, Inc. Método para la activación de linfocitos T colaboradores y composición para su uso en el método
EP2216041A4 (en) * 2007-11-20 2012-10-24 Nec Corp METHOD OF INDUCING A CYTOTOXIC T-CELL, CYTOTOXIC T-CELL INDUCTOR AND PHARMACEUTICAL COMPOSITION, AND VACCINE WITH THE INDUCTOR
AR083295A1 (es) 2010-10-05 2013-02-13 Univ Osaka Metodo para activar celulas t auxiliares
EP2792745B1 (en) * 2011-12-14 2017-11-15 National University Corporation Kochi University Modification of helper t cell-inducing polypeptide
AU2013207669C1 (en) 2012-01-13 2018-05-31 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
KR102158225B1 (ko) * 2012-12-17 2020-09-21 오츠카 세이야쿠 가부시키가이샤 헬퍼 t세포의 활성화 방법
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
PT2945647T (pt) * 2013-01-15 2020-11-26 Memorial Sloan Kettering Cancer Center Péptidos imunogénicos wt-1 e métodos de uso dos mesmos
US10588952B2 (en) 2013-03-29 2020-03-17 Sumitomo Dainippon Pharma Co., Ltd. Conjugate vaccine using trimming function of ERAP1
WO2014157692A1 (ja) 2013-03-29 2014-10-02 大日本住友製薬株式会社 Ｗｔ１抗原ペプチドコンジュゲートワクチン
CN116327902A (zh) 2015-11-20 2023-06-27 纪念斯隆凯特林癌症中心 用于治疗癌症的方法和组合物
EP3549957A4 (en) 2016-11-30 2020-08-05 Sumitomo Dainippon Pharma Co., Ltd. AUXILIARY PEPTIDE WT1, AND COMBINATION OF DUDIT PEPTIDE AND CONJUGATE PEPTIDE ANTIGENIC FOR CANCER
US20210100886A1 (en) 2017-03-30 2021-04-08 Sumitomo Dainippon Pharma Co., Ltd. Wt1 cancer antigen peptides and peptide conjugates comprising the peptides
US20200276285A1 (en) 2017-06-02 2020-09-03 Arizona Board Of Regents On Behalf Of Arizona State University A method to create personalized cancer vaccines
US12025615B2 (en) 2017-09-15 2024-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
WO2020067453A1 (ja) 2018-09-28 2020-04-02 大日本住友製薬株式会社 注射用組成物
TW202528332A (zh) 2019-02-28 2025-07-16 日商住友製藥股份有限公司 選擇可期待用於治療或預防癌之醫藥組合物之效果之對象之方法
WO2021067550A1 (en) 2019-10-02 2021-04-08 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer
TW202200188A (zh) 2020-05-12 2022-01-01 日商大日本住友製藥股份有限公司 用以處置癌症之醫藥組合物
CN118076382A (zh) 2021-08-12 2024-05-24 株式会社癌免疫研究所 用于治疗或预防癌症的药用组合物和方法

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5837249A (en) 1985-04-19 1998-11-17 The Wistar Institute Method for generating an immunogenic T cell response protective against a virus
US5726288A (en) 1989-11-13 1998-03-10 Massachusetts Institute Of Technology Localization and characterization of the Wilms' tumor gene
US5229115A (en) 1990-07-26 1993-07-20 Immunex Corporation Adoptive immunotherapy with interleukin-7
AU1570292A (en) 1991-02-07 1992-09-07 Board Of Trustees Of The University Of Illinois, The Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
CA2158281A1 (en) 1993-03-15 1994-09-29 Jay A. Berzofsky Peptide coated dendritic cells as immunogens
WO1995029240A1 (en) 1994-04-22 1995-11-02 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Isolation and characterization of a novel primate t-cell lymphotropic virus and the use of this virus or components thereof in diagnostics assays and vaccines
US5622835A (en) 1994-04-28 1997-04-22 The Wistar Institute Of Anatomy & Biology WT1 monoclonal antibodies
US5643786A (en) 1995-01-27 1997-07-01 The United States Of America As Represented By The Department Of Health And Human Services Method for isolating dendritic cells
US6156316A (en) 1995-05-08 2000-12-05 Sloan-Kettering Institute For Cancer Research Oncogene fusion protein peptide vaccines
JPH11171896A (ja) 1995-09-19 1999-06-29 Kirin Brewery Co Ltd 新規ペプチド化合物およびその医薬組成物
US5981217A (en) 1995-12-11 1999-11-09 Mayo Foundation For Medical Education And Research DNA encoding TGF-β inducible early factor-1 (TIEF-1), a gene expressed by osteoblasts
CA2243235C (en) 1996-01-17 2010-08-10 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
US6207375B1 (en) 1996-12-11 2001-03-27 Mayo Foundation For Medical Educational & Research TGF-β inducible early factor-1 (TIEF-1) and a method to detect breast cancer
ID27813A (id) 1998-01-28 2001-04-26 Corixa Corp Senyawa-senyawa untuk terapi dan diagnosa kanker paru-paru dan metoda untuk penggunaannya
PT1103564E (pt) 1998-07-31 2009-03-13 Int Inst Cancer Immunology Inc Antigénios de cancro com base no produto do gene supressor de tumor wt1
US20030072767A1 (en) * 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
US7063854B1 (en) 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US20120301492A1 (en) 1998-09-30 2012-11-29 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7144581B2 (en) 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
GB9823897D0 (en) 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
JP2002534478A (ja) * 1998-12-18 2002-10-15 エイブイアイ バイオファーマ， インコーポレイテッド 絨毛性ゴナドトロピンｄｎａワクチンおよび方法
CA2354369A1 (en) 1998-12-22 2000-06-29 Genset S.A. Complementary dna's encoding proteins with signal peptides
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
CA2367692A1 (en) 1999-03-15 2000-09-21 Introgen Therapeutics, Inc. Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses
US6593299B1 (en) 1999-04-21 2003-07-15 University Of Florida Research Foundation, Inc. Compositions and methods for controlling pests
AU7859900A (en) 1999-10-04 2001-05-10 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
CA2401070A1 (en) 2000-02-22 2001-08-30 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma
US20030082194A1 (en) 2000-02-22 2003-05-01 Alexander Gaiger Compositions and methods for diagnosis and therapy of malignant mesothelioma
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US6861234B1 (en) 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
EP1209226A3 (en) 2000-11-07 2002-06-05 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Maturation of dendritic cells by recombinant heat shock protein 70 (hsp70)
US20040053822A1 (en) * 2000-12-11 2004-03-18 John Fikes Inducing cellular immune responses to mage2/3 using peptide and nucleic acid compositions
US20040097703A1 (en) 2001-03-22 2004-05-20 Haruo Sugiyama Wt1 modified peptide
US8771702B2 (en) 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
ATE494905T1 (de) 2001-06-29 2011-01-15 Chugai Pharmaceutical Co Ltd Krebsimpfstoff mit einem krebs-antigen auf grundlage des produkts aus dem tumorunterdrückungsgen wt1 und einem kationischen liposom
US7553494B2 (en) * 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
WO2003028757A1 (en) 2001-09-28 2003-04-10 Haruo Sugiyama Novel method of inducing antigen-specific t cells
JPWO2003028758A1 (ja) 2001-09-28 2005-01-13 治夫 杉山 抗原特異的ｔ細胞の誘導方法
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
US20030175272A1 (en) 2002-03-07 2003-09-18 Medcell Biologics, Inc. Re-activated T-cells for adoptive immunotherapy
JP4365784B2 (ja) 2002-06-12 2009-11-18 株式会社癌免疫研究所 Ｈｌａ−ａ２４拘束性癌抗原ペプチド
WO2004084936A2 (en) 2003-02-06 2004-10-07 Cerus Corporation Modified free-living microbes, vaccine compositions and methods of use thereof
US20050008618A1 (en) 2003-02-27 2005-01-13 Howard Kaufman Composition for delivering an agent to a target cell and uses thereof
CA2514288C (en) 2003-03-05 2015-07-07 Dendreon Corporation Compositions and methods employing alternative reading frame polypeptides for the treatment of cancer and infectious disease
KR101431312B1 (ko) 2003-06-27 2014-08-20 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 Ｗｔ1 백신 적응 환자의 선택 방법
US20050147621A1 (en) 2003-10-10 2005-07-07 Higgins Darren E. Use of bacterial 5' untranslated regions for nucleic acid expression
PL2071028T3 (pl) 2003-11-05 2012-06-29 Int Inst Cancer Immunology Inc Pochodzący z WT1 peptyd antygenowy wiążący się z HLA-DR
CA2548135C (en) 2003-12-01 2014-04-22 Sloan-Kettering Institute For Cancer Research Synthetic hla binding peptide analogues and uses thereof
ES2324538T3 (es) 2003-12-05 2009-08-10 Multimmune Gmbh Anticuerpos anti-hsp terapeuticos y de diagnostico.
EP1550458A1 (en) 2003-12-23 2005-07-06 Vectron Therapeutics AG Synergistic liposomal adjuvants
EP1720565A1 (en) 2004-03-04 2006-11-15 Corixa Corporation Co-encapsulated wt1 polypeptide and immunostimulant microsphere formulations and methods thereof
US20050214268A1 (en) 2004-03-25 2005-09-29 Cavanagh William A Iii Methods for treating tumors and cancerous tissues
US20050221481A1 (en) 2004-03-30 2005-10-06 Istituto Superiore Di Sanita' Amplification of T cells from human cord blood in serum-deprived culture stimulated with stem cell factor, interleukin-7 and interleukin-2
EP2186896B1 (en) 2004-03-31 2015-11-04 International Institute of Cancer Immunology, Inc. Cancer antigen peptides derived from WT1
US9629927B2 (en) 2005-07-29 2017-04-25 Sloan-Kettering Institute For Cancer Research Single wall nanotube constructs and uses thereof
EP2565201B1 (en) * 2005-10-17 2014-11-26 Sloan-Kettering Institute For Cancer Research WT1 HLA class II-binding peptides and compositions and methods comprising same
RU2424247C2 (ru) 2005-11-30 2011-07-20 Интернэшнл Инститьют Оф Кэнсер Иммьюнолоджи, Инк. Пептид, индуцирующий цитотоксические т-клетки (цтл), способ индукции цтл, антитело, связывающееся с этим пептидом, применение пептида в фармацевтической композиции и для лечения или предупреждения рака, антигенпредставляющая клетка
DK2518149T3 (en) 2006-02-22 2016-01-11 Int Inst Cancer Immunology Inc HLA-A * 3303-LIMITED WT1 PEPTIDE AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME
WO2007119564A1 (ja) 2006-03-29 2007-10-25 International Institute Of Cancer Immunology, Inc. ＷＴ１ １７ＡＡ（－）アイソフォーム特異的ｓｉＲＮＡおよびその利用
EP3117836A1 (en) 2006-04-10 2017-01-18 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and uses thereof
WO2007120603A2 (en) 2006-04-10 2007-10-25 Sloan Kettering Institute For Cancer Research Immunogenic bcr-abl peptides and methods of use thereof
NZ720288A (en) 2006-12-27 2020-02-28 Harvard College Compositions and methods for the treatment of infections and tumors
CN101573448B (zh) 2006-12-28 2012-07-11 株式会社癌免疫研究所 Hla-a*1101限制的wt1肽及含有其的药物组合物
EP2127671B1 (en) 2007-02-07 2016-09-14 Nec Corporation Therapeutic agent for cancer
ES2559062T3 (es) 2007-02-27 2016-02-10 International Institute Of Cancer Immunology, Inc. Método para la activación de linfocitos T colaboradores y composición para su uso en el método
US20090035360A1 (en) 2007-05-24 2009-02-05 Dominique Ingrid Lemoine Lyophilised antigen composition
KR100995340B1 (ko) 2007-11-19 2010-11-19 재단법인서울대학교산학협력재단 자연 살해 ｔ 세포의 리간드와 항원을 적재한 단핵구 또는미분화 골수성 세포를 포함하는 백신
KR101610664B1 (ko) 2007-12-05 2016-04-08 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 암 백신 조성물
KR100900837B1 (ko) 2007-12-07 2009-06-04 (주)두비엘 리포펩타이드와 폴리(ｉ:ｃ)를 아쥬반트로 포함하는 강력한백신 조성물
CN102076843A (zh) 2008-05-19 2011-05-25 艾杜罗生物科技公司 包含prfa*突变体李斯特菌的组合物及其使用方法
US20110318380A1 (en) 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
AR076349A1 (es) 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
US20130288236A1 (en) 2009-11-11 2013-10-31 Quest Diagnostics Investments Incorporated Wt1 mutations for prognosis of myeloproliferative disorders
US20110136141A1 (en) 2009-12-03 2011-06-09 Abbott Laboratories Peptide reagents and method for inhibiting autoantibody antigen binding
US20110223187A1 (en) 2010-02-15 2011-09-15 Vafa Shahabi Live listeria-based vaccines for central nervous system therapy
EP4159226A1 (en) 2010-08-24 2023-04-05 University of Pittsburgh - Of the Commonwealth System of Higher Education Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
AR083295A1 (es) 2010-10-05 2013-02-13 Univ Osaka Metodo para activar celulas t auxiliares
CN103826629A (zh) 2011-03-11 2014-05-28 吉里德卡利斯托加公司 恶性血液病的组合治疗
CN103764826A (zh) 2011-06-28 2014-04-30 株式会社癌免疫研究所 肽癌抗原-特异性t细胞的受体基因
CA2843386A1 (en) 2011-07-29 2013-02-07 Riken Cell for use in immunotherapy which contains modified nucleic acid construct encoding wilms tumor gene product or fragment thereof, method for producing said cell, and said nucleic acid construct
US9539299B2 (en) 2011-10-27 2017-01-10 International Institute Of Cancer Immunology, Inc. Combination therapy with WT1 peptide vaccine and temozolomide
EP2792745B1 (en) 2011-12-14 2017-11-15 National University Corporation Kochi University Modification of helper t cell-inducing polypeptide
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
RU2665548C2 (ru) 2012-05-03 2018-08-30 Фред Хатчинсон Кансэр Рисёч Сентер Способ получения клеток, экспрессирующих т-клеточный рецептор
ES2655031T3 (es) 2012-07-02 2018-02-16 Sumitomo Dainippon Pharma Co., Ltd. Preparación transdérmica de péptido antigénico del cáncer
EP2911683B1 (en) 2012-10-23 2019-09-25 Ubivac, LLC Allogeneic autophagosome-enriched composition for the treatment of disease
KR102158225B1 (ko) 2012-12-17 2020-09-21 오츠카 세이야쿠 가부시키가이샤 헬퍼 t세포의 활성화 방법
EP2940134A4 (en) 2012-12-26 2016-08-10 Biocomo Inc USING THE HUMAN PARAIN FLUENZAVIRUS TYPE 2 VEGETABLE VACCINE
PT2945647T (pt) 2013-01-15 2020-11-26 Memorial Sloan Kettering Cancer Center Péptidos imunogénicos wt-1 e métodos de uso dos mesmos
US10449144B2 (en) 2013-02-05 2019-10-22 Nitto Denko Corporation WT1 peptide cancer vaccine composition for transdermal administration
IN2014CH00393A (pl) 2013-02-05 2015-04-03 Nitto Denko Corp
JP6497691B2 (ja) 2013-02-05 2019-04-10 日東電工株式会社 粘膜投与用ｗｔ１ペプチド癌ワクチン組成物
RU2685933C2 (ru) 2013-02-05 2019-04-23 Нитто Денко Корпорейшн Композиция противораковой вакцины, содержащая пептид wt1, для трансдермального введения
US10137182B2 (en) 2013-02-14 2018-11-27 Immunocellular Therapeutics, Ltd. Cancer vaccines and vaccination methods
JP6294868B2 (ja) 2013-03-12 2018-03-14 大日本住友製薬株式会社 液体水性組成物
KR20150130284A (ko) 2013-03-15 2015-11-23 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암 백신 및 이를 이용한 치료 방법
WO2014157692A1 (ja) 2013-03-29 2014-10-02 大日本住友製薬株式会社 Ｗｔ１抗原ペプチドコンジュゲートワクチン
ES2675020T3 (es) 2013-04-25 2018-07-05 Vaximm Ag Vectores basados en Salmonella para inmunoterapia del cáncer dirigida al gen WT1 del tumor de Wilms
CN111781359A (zh) 2013-05-13 2020-10-16 株式会社癌免疫研究所 用于预测免疫疗法的临床效果的方法
US10898555B2 (en) 2013-07-02 2021-01-26 Japanese Foundation For Cancer Research Cellular immunity inducing vaccine
EP3071594A4 (en) 2013-11-22 2017-05-03 The Board of Trustees of the University of Illionis Engineered high-affinity human t cell receptors
SG11201604911VA (en) 2013-12-18 2016-07-28 Vaximm Gmbh Novel msln targeting dna vaccine for cancer immunotherapy
EP4070818A3 (en) 2014-01-06 2023-01-11 The Trustees of the University of Pennsylvania Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
CA2939093A1 (en) 2014-02-14 2015-08-20 Immune Design Corp. Immunotherapy of cancer through combination of local and systemic immune stimulation
EP3112378B1 (en) 2014-02-26 2020-06-24 Tella, Inc. Wt1 antigenic polypeptide, and anti-tumor agent containing said polypeptide
US10023841B2 (en) 2014-05-23 2018-07-17 Baylor Research Institute Methods and compositions for treating breast cancer with dendritic cell vaccines
KR102797324B1 (ko) 2014-12-11 2025-04-22 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 혈관 신생병의 면역 요법
US10695385B2 (en) 2015-06-25 2020-06-30 National University Corporation Kobe University Oral cancer vaccine
WO2017049074A1 (en) 2015-09-18 2017-03-23 Moderna Therapeutics, Inc. Polynucleotide formulations for use in the treatment of renal diseases
CN116327902A (zh) * 2015-11-20 2023-06-27 纪念斯隆凯特林癌症中心 用于治疗癌症的方法和组合物

Also Published As

Publication number Publication date
WO2007120673A2 (en) 2007-10-25
US20160368948A1 (en) 2016-12-22
US20230265122A1 (en) 2023-08-24
EP3117836A1 (en) 2017-01-18
EP3834836A1 (en) 2021-06-16
EP2010209A2 (en) 2009-01-07
EP2010209B1 (en) 2016-06-15
US11414457B2 (en) 2022-08-16
US20190270776A1 (en) 2019-09-05
CA2645766A1 (en) 2007-10-25
ES2591029T3 (es) 2016-11-24
US20100092522A1 (en) 2010-04-15
WO2007120673A3 (en) 2008-11-06
US9265816B2 (en) 2016-02-23
EP2010209A4 (en) 2010-03-31

Similar Documents

Publication Publication Date Title
PL2010209T3 (pl) Immunogeniczne peptydy WT-1 i sposoby ich użycia
IL197501A0 (en) Modifications of cupredoxin derived peptides and methods of use thereof
EP2068898A4 (en) BONE CEMENT AND APPLICATION METHOD THEREFOR
ZA201003625B (en) 5-anilinoimidazopyridines and methods of use
IL196462A0 (en) Substituted acylanilides and methods of use thereof
IL197185A0 (en) Substituted acylanilides and methods of use thereof
EP2021455A4 (en) SYSTEM FOR PREPARING CYTOBLOCS AND METHODS OF USE THEREOF
EP2091588A4 (en) CARDIAL DEVICE AND USE METHOD THEREFOR
ZA200802501B (en) Indenoisoquinolinone analogs and methods of use thereof
IL222947A0 (en) Luminaire and methods of use
EP2054063A4 (en) 4-AMINOCHINAZOLINE DERIVATIVES AND METHOD FOR THEIR USE
ZA200905626B (en) Adjuvants and methods of using them
EP2023718A4 (en) CREATINLIGATE COMPOUNDS AND APPLICATION METHOD THEREFOR
EP2021555A4 (en) STRUCTURAL ELEMENT AND METHODS OF USE THEREOF
ZA200900203B (en) Adjuvants and methods of use
IL194777A0 (en) Hcv coreceptor and methods of use thereof
IL206125A0 (en) Azaindolizines and methods of use
EP2185719A4 (en) RANTES ANTIBODIES AND METHOD FOR THEIR USE
ZA200905741B (en) Indenoisoquinolinone analogs and methods of use thereof
EP2478005A4 (en) CROSSLINKED CRYSTALS AND CRYSTALS OF PROTEIN A AND METHODS OF USE THEREOF
GB0908868D0 (en) Depsipeptide and their therapeutic use
GB0615635D0 (en) Immunogenic proteins and uses thereof
IL214762A0 (en) Modifications of cupredoxin derives peptides and methods of use thereof
EP2229446A4 (en) HYDROGENASE POLYPEPTIDE AND USE METHOD
GB0818065D0 (en) Immunogenic peptides and uses thereof